{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:28:47Z","timestamp":1793737727976,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development & Commercialization Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jagp.2026.06.015","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:31:03Z","timestamp":1782851463000},"page":"1469-1476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brexpiprazole With Antidepressants for Agitation in Alzheimer\u2019s Dementia: Post Hoc Analysis"],"prefix":"10.1016","volume":"34","author":[{"given":"C. Brendan","family":"Montano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeda R.","family":"Chumki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton M.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton P.","family":"Porsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2026.06.015_bib0001","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/gps.5030","article-title":"Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia","volume":"34","author":"Halpern","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2026.06.015_bib0002","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/gps.5604","article-title":"Impact of agitation in long-term care residents with dementia in the United States","volume":"36","author":"Fillit","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2026.06.015_bib0003","series-title":"Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI)","author":"Cohen-Mansfield","year":"1991"},{"key":"10.1016\/j.jagp.2026.06.015_bib0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13696998.2023.2291966","article-title":"A real-world assessment of healthcare costs associated with agitation in Alzheimer\u2019s dementia","volume":"27","author":"Grossberg","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.jagp.2026.06.015_bib0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/14713012251340463","article-title":"Agitation in individuals with Alzheimer\u2019s disease: an assessment of behaviors using the Cohen-Mansfield Agitation Inventory in community-dwellers and impact on caregiver experience","volume":"25","author":"Grossberg","year":"2026","journal-title":"Dementia (London)"},{"key":"10.1016\/j.jagp.2026.06.015_bib0006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","article-title":"Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study","volume":"172","author":"Peters","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2026.06.015_bib0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/00325481.2025.2517535","article-title":"A US-based practitioner\u2019s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer\u2019s dementia \u2013 recommendations of an expert, multispecialty advisory panel","volume":"137","author":"Grossberg","year":"2025","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jagp.2026.06.015_bib0008","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2026.06.015_bib0009","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jagp.2026.06.015_bib0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40263-025-01200-9","article-title":"Safety and tolerability of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of three randomized trials and an extension trial","volume":"39","author":"Shah","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jagp.2026.06.015_bib0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3233\/JAD-240491","article-title":"Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer\u2019s disease: a 12-week, active-treatment, extension trial","volume":"102","author":"Behl","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jagp.2026.06.015_bib0012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40261-025-01517-9","article-title":"Efficacy of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of randomized controlled trials","volume":"46","author":"Cummings","year":"2026","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jagp.2026.06.015_bib0013","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.2020.8519","article-title":"Prevalence of psychotropic and opioid prescription fills among community-dwelling older adults with dementia in the US","volume":"324","author":"Maust","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2026.06.015_bib0014","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2021.1195","article-title":"Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US","volume":"325","author":"Maust","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2026.06.015_bib0015","article-title":"Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: a systematic review and network meta-analysis","volume":"15","author":"Chen","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jagp.2026.06.015_bib0016","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jpsychires.2024.12.005","article-title":"Efficacy and tolerability of antidepressants monotherapy for behavioral and psychological symptoms of dementia: a meta-analysis of randomized controlled trials","volume":"181","author":"Dong","year":"2025","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jagp.2026.06.015_bib0017","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/03007995.2025.2552278","article-title":"Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer\u2019s disease","volume":"41","author":"Stroud","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jagp.2026.06.015_bib0018","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jagp.2026.06.015_bib0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jagp.2026.06.015_bib0020","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jagp.2026.06.015_bib0021","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1017\/S1041610222001041","article-title":"Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition","volume":"36","author":"Sano","year":"2024","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jagp.2026.06.015_bib0022","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/NDT.S501207","article-title":"Preclinical evidence for the use of brexpiprazole + antidepressant treatment for major depressive disorder and post-traumatic stress disorder: a systematic review","volume":"21","author":"Brubaker","year":"2025","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jagp.2026.06.015_bib0023","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin\u2013dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jagp.2026.06.015_bib0024","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1017\/S1092852924000427","article-title":"An overview of the pathophysiology of agitation in Alzheimer\u2019s dementia with a focus on neurotransmitters and circuits","volume":"29","author":"Cummings","year":"2024","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jagp.2026.06.015_bib0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14737175.2013.811901","article-title":"Second-generation antipsychotics in the treatment of major depressive disorder: current evidence","volume":"13","author":"Han","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jagp.2026.06.015_bib0026","first-page":"371.e311","article-title":"Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics","volume":"19","author":"Seppala","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jagp.2026.06.015_bib0027","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/gps.4952","article-title":"Adjunctive brexpiprazole for elderly patients with major depressive disorder: an open-label, long-term safety and tolerability study","volume":"33","author":"Lepola","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jagp.2026.06.015_bib0028","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/1573400512666160816095900","article-title":"Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment","volume":"12","author":"Nelson","year":"2016","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.jagp.2026.06.015_bib0029","unstructured":"Axsome Therapeutics Inc.: Auvelity\u00ae (dextromethorphan hydrobromide\/bupropion hydrochloride) extended-release tablets, for oral use. Prescribing information [United States], 2026. Available at: https:\/\/www.axsome.com\/auvelity-prescribing-information.pdf. Accessed July 17, 2026"},{"key":"10.1016\/j.jagp.2026.06.015_bib0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/geriatrics9030064","article-title":"Treating depression in dementia patients: a risk or remedy \u2013 a narrative review","volume":"9","author":"Sultan","year":"2024","journal-title":"Geriatrics (Basel)"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748126004501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748126004501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:55:21Z","timestamp":1793735721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748126004501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1064748126004501"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2026.06.015","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brexpiprazole With Antidepressants for Agitation in Alzheimer\u2019s Dementia: Post Hoc Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2026.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Association for Geriatric Psychiatry.","name":"copyright","label":"Copyright"}]}}